

2021 FORECAST:
A GUIDE FOR COMBATING ANTIMICROBIAL RESISTANCE

New Antimicrobials: What you need to know

When new antimicrobials come to market, microbiology lab personnel need to know when these drugs might be used and when resistance to the drug might be expected. Several new antimicrobials have come to market recently and this document will help labs sort through these important issues.

For some MDRO infections, like CRE-NDM infections, there are few treatment options. Especially for these infections, it is important to get a preview of what therapies are in the development pipeline. This document highlights how some old drugs are used in new ways. With increasing frequency, ESβL-producing *Enterobacterales* (formerly *Enterobacteriaceae*) are causes of community-associated urinary tract infections (UTI). These infections may need treatment with drugs that were rarely used for outpatient UTI treatment, (e.g., ertapenem).

Beckman Coulter is committed to partnering with healthcare professionals to combat antimicrobial resistance. We can best address this growing global-health crisis together.

In that spirit, we updated our previous forecast of antimicrobial-resistance profiles and combination-therapy options to advance new considerations for treating evolving infections. We hope this guide supports your efforts as you explore new agents to fight multidrug-resistant organisms.

BECKMAN COULTER

New Antimicrobials: What you need to know

BECKMAN COULTER

Hard-to-treat Bacterial Infections	Recently Approved Antimicrobials*	Promising Antimicrobials in Late-phase Development	What else do you need to know?
URINARY TRACT INFECTIONS CAUSED BY:			
ESβL-producing *Enterobacterales*†	These drugs are not new, but were uncommonly used for UTI treatment: Uncomplicated UTI: › Oral Fosfomycin (*E. coli* only) Complicated UTI: › Ertapenem › Imipenem › Meropenem	› Tebipenem › Sulopenem › Cefepime-enmetazobactam	With increasing frequency, UTIs caused by ESβL-producing *Enterobacterales* are seen in outpatients with no previous healthcare exposures. Including ESβL drugs on a UTI AST panel will be important. New drugs like ceftolozane-tazobactam, ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam may be active for these infections, but these drugs may be reserved for serious infections with limited treatment options.
SERIOUS INFECTIONS CAUSED BY:			
MRSA	› Eravacycline › Omadacycline › Lefamulin	› Iclaprim › Ceftobiprole › Contezolid › Gepotidacin	See Resistant Profile table for more information.
VRE	› Eravacycline › Omadacycline	› Contezolid	CLSI revised daptomycin breakpoints in 2019 to account for high-dose daptomycin treatment of VR-*E. faecium* infections. *E. faecium* are the most common VRE species.
CRE-KPC (most common class A carbapenemase)	› Ceftazidime-avibactam › Meropenem-vaborbactam › Imipenem-relebactam › Plazomycin	› Cefepime-taniborbactam › Aztreonam-avibactam	N/A
CRE-OXA 48-like carbapenemase (most common class C carbapenemase)	› Ceftazidime-avibactam › Imipenem-relebactam › Plazomycin › Cefiderocol	› Cefepime-taniborbactam › Aztreonam-avibactam	N/A
CRE-NDM (most common class D carbapenemase)	› Plazomycin‡ › Cefiderocol	› Cefepime-taniborbactam › Aztreonam-avibactam	‡With increasing frequency, CRE-NDM isolates also carry a 16S rRNA methylase which confers resistance to all aminoglycosides including plazomycin.
CR-*Pseudomonas aeruginosa*	› Ceftolozane-tazobactam › Cefiderocol	› Cefepime-taniborbactam	Most CR-P. *aeruginosa* do not produce a carbapenemase, but with increasing frequency VIM-producing CR-P. *aeruginosa* are causes of outbreaks in healthcare facilities. VIM is a class D carbapenemase and, like NDM, is not inhibited by most ß-lactamase inhibitors.
CR-*Acinetobacter* spp.	Cefiderocol	Sulbactam-durlobactam	Minocycline may be active.

*See treatment guidelines for recommended use of antimicrobials by infection type.

†The term Enterobacterales is used instead of Enterobacteriaceae because this new name was adopted by both CLSI (2020 documents) and EUCAST.

Resistant Profiles for New Antimicrobials

BECKMAN COULTER

Antimicrobial	Target Organisms	Resistance	Other comments
Delafloxacin	› *Staphylococcus* spp. › *Streptococcus* spp. › *Enterococcus* spp.	Requires double mutations in both *gyr*A and *par*C for resistance. The other fluoroquinolones are resistant after one mutation in each gene.	Because the number of mutations required for resistance differs among fluoroquinolones, isolates may test resistant to drugs like ciprofloxacin and levofloxacin, but test susceptible to delafloxacin.
	› *Enterobacterales* › *Pseudomonas aeruginosa*	Like other fluoroquinolones, defafloxacin resistance is common among Gram-negative bacteria.	N/A
Eravacycline§	› *Enterobacterales*	Resistance to eravacycline occurs in isolates of *Enterobacterales*, *S. aureus* and *Enterococcus* spp.	Cross-resistance occurs between tigecycline and eravacycline in *Enterobacterales*, *Staphylococcus* and *Enterococcus*.
	› *Staphylococcus aureus* › *Enterococcus* spp. › *Streptococcus anginosus* group		
Lefamulin	› *Staphylococcus aureus* (methicillin-susceptible isolates) › *Streptococcus pneumoniae*	Resistance to lefamulin occurs in Gram-positive bacteria, but is uncommon and more likely to occur in isolates of animal origin than isolates of human origin.	N/A
Omadacycline	› *Enterobacterales*	Some, but not all, mechanisms of tetracycline resistance can also confer resistance to omadacycline.	Tetracycline-resistant Gram-positive isolates can test susceptible to omadacycline. Tetracycline-resistant *Enterobacterales* are more likely to test resistant to omadacycline.
	› *Staphylococcus* spp. › *Enterococcus* spp. › *Streptococcus* spp.		
Ceftazidime-avibactam§	› *Enterobacterales*	Mutations can occur in the KPC gene that confer resistance to ceftazidime-avibactam.	Ceftazidime-avibactam is not active against Gram-negative bacteria producing class B carbapenemases. These are the metallo-ß-lactamases like NDM, IMP, and VIM.
Meropenem-vaborbactam§	› *Enterobacterales*	Meropenem-vaborbactam is active against CRE with class A carbapenemases like KPC. No resistance reported.	Meropenem-vaborbactam is not active against CRE with class D (e.g., OXA-48-like) or class B (e.g., NDM, IMP and VIM) carbapenemases.
Imipenem-relebactam	› *Enterobacterales*	Imipenem-relebactam is active against CRE with class A (e.g., KPC) and CRE with class D carbapenemases (e.g., OXA-48 like), but activity is greatest against CRE-KPC.	Imipenem-relebactam is not active against CRE with class B carbapenemases (e.g., NDM, IMP, and VIM).
Plazomicin	› *Enterobacterales*	Resistance occurs in isolates carrying plasmid-mediated genes encoding 16S methylases. These genes also confer resistance to all aminoglycosides.	The 16S methylase genes are most commonly found in CRE-NDM isolates and only rarely in other types of CRE.
Cefiderocol	› *Enterobacterales* › *Pseudomonas aeruginosa* › *Acinetobacter* spp.	Isolates with NDM carbapenemases and PER ESβLs can test resistant, but the enzyme alone is not sufficient for resistance. Other factors likely contribute to the elevated cefiderocol MIC.	The PER ESβL is relatively uncommon. It is found in *P. aeruginosa and Acinetobacter* spp.

§Drugs on MicroScan panels.

Acronyms

ESβL	Extended-spectrum β-lactamase	**NDM**	New Delhi Metallo-β-lactamase
CR	Carbapenem-resistant	**OXA**	Oxacillinase
CRE	Carbapenem-resistant *Enterobacterales*	**PER**	*Pseudomonas* extended resistance
CRPA	Carbapenem-resistant *Pseudomonas aeruginosa*	**UTI**	Urinary tract infection
KPC	*Klebsiella pneumoniae* carbapenemase	**VIM**	Verona Integron-Borne Metallo-β-lactamase
MDRO	Multidrug-resistant organism	**VRE**	Vancomycin-resistant *Enterococcus*
MRSA	Methicillin-resistant *Staphylococcus aureus*		

Acquired Carbapenemases in *Enterobacterales*

Molecular Class	Example Types	Activity
A	**KPCs** Also others, but not common	Largest number, usually on plasmid, most inactivated by clavulanic acid
B	**NDM, VIM, IMP** *Enterobacterales*, *P. aeruginosa*, *Acinetobacter*	Metallo β-lactamases (MBL): Resistant to many drugs, including carbapenems › Enzyme does not hydrolyze aztreonam › May require zinc for expression
C	—	None here
D	**OXA enzymes**	***K. pneumoniae* (OXA-48)** OXA-23, -40, -51, -58 in *Acinetobacter* Others in *Pseudomonas* and other non-*Enterobacterales*

References & Resources

Breakpoints (i.e., Interpretive Criteria)

CLSI M100: https://clsi.org/standards/products/free-resources/access-our-free-resources/

EUCAST Clinical Breakpoints: http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_9.0_Breakpoint_Tables.pdf

FDA Antibacterial Susceptibility Test Interpretive Criteria: https://www.fda.gov/drugs/development-resources/antibacterial-susceptibility-test-interpretive-criteria

Antimicrobial Developmental Pipeline

The Antibiotic Pipeline: https://www.pewtrusts.org/en/research-and-analysis/data-visualizations/2014/antibiotics-currently-in-clinical-development

Surveillance Data

1. Canver MC, et al. 2019. Activity of imipenem-relebactam and comparator agents against genetically characterized Isolates of carbapenem-resistant *Enterobacteriaceae*. Antimicrobial Agents and Chemotherapy Vol 63(9).
2. Carvalhaes, CG, et al. 2020. In vitro activity and potency of the novel oxazolidinone contezolid (MRX-I) tested against Gram-positive clinical isolate from the United States and Europe. Antimicrobial Agents and Chemotherapy Vol 64(11).
3. Castanheira M, et al. 2018. Activity of plazomicin compared with other aminoglycosides against isolates from European and adjacent countries, including *Enterobacteriaceae* molecularly characterized for aminoglycoside-modifying enzymes and other resistance mechanisms. Journal of Antimicrobial Chemotherapy 73(12).
4. Flamm RK, et al. 2017. Gepotidacin (GSK2140944) in vitro activity against Gram-positive and Gram-negative bacteria. Antimicrobial Agents and Chemotherapy Vol 61(7).
5. Jorgensen SCJ, et al. 2018. Delafloxacin: Place in Therapy and Review of Microbiologic, Clinical and Pharmacologic Properties. Infectious Diseases and Therapy Vol 7(2).
6. Kohira N, et al. 2020. Reduced susceptibility mechanism to cefiderocol, a siderophore cephalosporin, among clinical isolates from a global surveillance programme (SIDERO-WT-2014). Journal of Global Antimicrobial Resistance Vol22.
7. Pana ZD, et al. 2018. Treatment of extended-spectrum ß-lactamase-producing *Enterobacteriaceae* (ESβLs) infections: what have we learned until now? F1000Research:1347.
8. Petty LA, et al. 2018. Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant *Enterobacteriacea*. Infection and Drug Resistance Vol 11.
9. Pfaller MA, et al. 2018. Surveillance of omadacycline activity tested against clinical Isolates from the United States and Europe as part of the 2016 SENTRY Antimicrobial Surveillance Program. Antimicrobial Agents & Chemotherapy Vol 62(4).
10. Pfaller MA, et al. 2019. Ceftobiprole activity against Gram-positive and -negative pathogens collected from the United States in 2006 and 2016. Antimicrobial Agents and Chemotherapy Vol 63(1).
11. Mendes RE, et al. 2019. Low prevalence of Gram-positive isolates showing elevated lefamulin MIC results during the surveillance program for 2015 to 2016 and characterization of resistance mechanisms. Antimicrobial Agents & Chemotherapy Vol 63(4).
12. Shields RK, et al. 2017. Emergence of ceftazidime-avibactam resistance due to plasmid-borne bla_{KPC-3} mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections. Antimicrobial Agents & Chemotherapy Vol 61(3).
13. Seifert H, et al. 2020. In vitro activity of sulbactam/durlobactam against global sioaltes of carbapenem-resistant *Acinetobacter baumannii*. Journal of Antimicrobial Chemotherapy Vol 75.
14. Sutcliffe JA, et al. 2013. Antibacterial Activity of Eravacycline (TP-434), a Novel Fluorocycline, against Hospital and Community Pathogens. Antimicrobial Agents & Chemotherapy Vol 57(11).

For Beckman Coulter's worldwide office locations and phone numbers, please visit www.beckmancoulter.com/contact

FL-290419 | 2020-8355